Sign In
BREAKEVENResult: BREAKEVEN0.0%0.0R|LONGConditional · 66 (was 61)|$1168.53 → $1168.539d 6hView in Radar →
LLY

LLY

NYSEReanalysis
Completed
Swing3 Models · Review Snapshot: Sep 25, 2026, 6:25 PM
Claude Opus 4.8 Fast, DeepSeek V4 Flash +1
HOLD CONSENSUS
1/3 EXIT votes — no EXIT supermajority
CO4.8F HoldDSV4F ExitMistr Hold
Trigger
Intraday Discovery — Eli Lilly and Company Receives FDA Approval for Once-Weekly Insulin Onswik
Conviction 66
Key Disagreements
  • •Mistral Large 2512 argues HOLD because LLY's original thesis remains intact, supported by fresh FDA approvals for Onswik and prior catalysts (Inluriyo+Verzenio and Mounjaro label expansion), which expand the company's addressable markets and reinforce fundamental growth. Technical assertion withheld pending a checked measurement. The path to the $1240 target is still feasible, and the stop at $1140 has not been compromised.
  • •DeepSeek V4 Flash argues EXIT because Technical assertion withheld pending a checked measurement. LLY is underperforming its own sector (XLV +0.21% vs LLY -0.25%), signaling idiosyncratic weakness. The regime has shifted from calm/bullish to No Edge/neutral with medium risk, removing the supportive macro backdrop. The original premortem rejection scenario is activating, and with only 14.6% progress toward target, the risk/reward has shifted against holding.
  • •What changed: Technical assertion withheld pending a checked measurement. LLY began underperforming XLV. Regime shifted from calm/bullish to No Edge/neutral.
Hold Case
Mistral Large 251281%

LLY's original thesis remains intact, supported by fresh FDA approvals for Onswik and prior catalysts (Inluriyo+Verzenio and Mounjaro label expansion), which expand the company's addressable markets and reinforce fundamental growth. Technical assertion withheld pending a checked measurement. The path to the $1240 target is still feasible, and the stop at $1140 has not been compromised.

Claude Opus 4.8 Fast69%

Technical assertion withheld pending a checked measurement. The stop at $1140 is untouched, price is +0.9% from entry, and the $1240 target remains feasible with only the $1186 barrier left to reclaim. Strong fundamentals (33.5% margins, +27% EPS surprise, dominant GLP-1 share) keep the multi-week swing thesis intact.

Exit Case
DeepSeek V4 Flash55%

Technical assertion withheld pending a checked measurement. LLY is underperforming its own sector (XLV +0.21% vs LLY -0.25%), signaling idiosyncratic weakness. The regime has shifted from calm/bullish to No Edge/neutral with medium risk, removing the supportive macro backdrop. The original premortem rejection scenario is activating, and with only 14.6% progress toward target, the risk/reward has shifted against holding.

What Could Go Wrong If We HOLD?
  • →The single most likely reason the HOLD verdict is wrong is if price fails to reclaim the $1186.80 resistance level and instead breaks below the $1161.39 support, invalidating the original thesis and closing the path to the $1240 target.
  • →Failed breakout at $1186 resistance with deteriorating momentum, sector underperformance, and regime deterioration — the original premortem rejection scenario is activating.

Individual Model Review

Claude Opus 4.8 Fast
HOLD69% confidence
Analysis Outcome
HOLD
69% confidence

Technical assertion withheld pending a checked measurement. The stop at $1140 is untouched, price is +0.9% from entry, and the $1240 target remains feasible with only the $1186 barrier left to reclaim. Strong fundamentals (33.5% margins, +27% EPS surprise, dominant GLP-1 share) keep the multi-week swing thesis intact.

Hold/Exit CompetitionHold 69% vs Exit 51%Winner: HOLD
Hold 69%Δ 18%Exit 51%
Hold Case69%

Technical assertion withheld pending a checked measurement. The stop at $1140 is untouched, price is +0.9% from entry, and the $1240 target remains feasible with only the $1186 barrier left to reclaim. Strong fundamentals (33.5% margins, +27% EPS surprise, dominant GLP-1 share) keep the multi-week swing thesis intact.

▼ Click to expand
Exit Case51%

Technical assertion withheld pending a checked measurement. A HIGH-impact macro cluster on Sep 30-Oct 2 raises the odds of a risk-off pullback that breaks the $1161 support shelf before the $1240 target is reached, which would invalidate the breakout path and justify closing the position.

▼ Click to expand
Claude-Opus-4.8-Fast98.6k tokensCost: $$
DeepSeek V4 Flash
EXIT55% confidence
Analysis Outcome
EXIT
55% confidence

Technical assertion withheld pending a checked measurement. LLY is underperforming its own sector (XLV +0.21% vs LLY -0.25%), signaling idiosyncratic weakness. The regime has shifted from calm/bullish to No Edge/neutral with medium risk, removing the supportive macro backdrop. The original premortem rejection scenario is activating, and with only 14.6% progress toward target, the risk/reward has shifted against holding.

Failed breakout at $1186 resistance with deteriorating momentum, sector underperformance, and regime deterioration — the original premortem rejection scenario is activating.

Hold/Exit CompetitionExit 55% vs Hold 49%Winner: EXIT
Exit 55%Δ 6%Hold 49%
Exit Case55%

Technical assertion withheld pending a checked measurement. LLY is underperforming its own sector (XLV +0.21% vs LLY -0.25%), signaling idiosyncratic weakness. The regime has shifted from calm/bullish to No Edge/neutral with medium risk, removing the supportive macro backdrop. The original premortem rejection scenario is activating, and with only 14.6% progress toward target, the risk/reward has shifted against holding.

▼ Click to expand
Hold Case49%

The original catalyst thesis of FDA approvals (Onswik, Inluriyo, Mounjaro) and strong Foundayo adoption remains fundamentally intact. Price is still above the $1161.39 support shelf and the $1140 stop provides a well-defined risk boundary. The pullback from $1188.33 could be a healthy retest before the next leg higher toward $1240 within the remaining 11 days.

▼ Click to expand
DeepSeek-V4-Flash71.2k tokensCost: $$
Mistral Large 2512
HOLD81% confidence
Analysis Outcome
HOLD
81% confidence

LLY's original thesis remains intact, supported by fresh FDA approvals for Onswik and prior catalysts (Inluriyo+Verzenio and Mounjaro label expansion), which expand the company's addressable markets and reinforce fundamental growth. Technical assertion withheld pending a checked measurement. The path to the $1240 target is still feasible, and the stop at $1140 has not been compromised.

Hold/Exit CompetitionHold 81% vs Exit 19%Winner: HOLD
Hold 81%Δ 62%Exit 19%
Hold Case81%

LLY's original thesis remains intact, supported by fresh FDA approvals for Onswik and prior catalysts (Inluriyo+Verzenio and Mounjaro label expansion), which expand the company's addressable markets and reinforce fundamental growth. Technical assertion withheld pending a checked measurement. The path to the $1240 target is still feasible, and the stop at $1140 has not been compromised.

▼ Click to expand
Exit Case19%

The exit case would strengthen if LLY fails to reclaim the $1186.80 resistance level and breaks below the $1161.39 support, signaling a failed breakout and invalidating the original thesis. Additionally, if the Healthcare sector (XLV) weakens further or macro regime shifts materially disrupt risk appetite, the risk/reward for the position would deteriorate.

▼ Click to expand
Mistral-Large-251271.1k tokensCost: $$

Run Summary

Intraday discovery triggered reanalysis on LLY. Verdict: HOLD (1/3 EXIT; requires 2). Conviction: 66.